Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C30H32ClN3O8S |
Molecular Weight | 630.108 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C(OC)=C1)S(=O)(=O)N2C(=O)[C@@](N3C[C@H](O)C[C@H]3C(=O)N(C)C)(C4=CC(Cl)=CC=C24)C5=C(OC)C=CC=C5
InChI
InChIKey=NJXZWIIMWNEOGJ-WEWKHQNJSA-N
InChI=1S/C30H32ClN3O8S/c1-32(2)28(36)24-15-19(35)17-33(24)30(21-8-6-7-9-25(21)41-4)22-14-18(31)10-12-23(22)34(29(30)37)43(38,39)27-13-11-20(40-3)16-26(27)42-5/h6-14,16,19,24,35H,15,17H2,1-5H3/t19-,24+,30+/m1/s1
Molecular Formula | C30H32ClN3O8S |
Molecular Weight | 630.108 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Nelivaptan is a selective, orally active, non-peptide vasopressin receptor antagonist selective for the V1B subtype. It showed promise in preclinical animal models and advanced to phase II clinical trials for the treatment of anxiety and depression; however, in 2008, Sanofi-Aventis announced that further development of this drug had been halted.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11959912
Curator's Comment: the referenced study was conducted on rat
Originator
Sources: https://patents.google.com/patent/US20060211685A1
Curator's Comment: # Boehringer Ingelheim International GmbH
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P47901 Gene ID: 553.0 Gene Symbol: AVPR1B Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/11959912 |
1.54 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. | 2002 Apr 30 |
|
Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. | 2002 Mar |
|
Selectivity of d[Cha4]AVP and SSR149415 at human vasopressin and oxytocin receptors: evidence that SSR149415 is a mixed vasopressin V1b/oxytocin receptor antagonist. | 2005 Nov |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11959912
Nelivaptan was prepared as a solution in physiological saline containing 0.1% Tween80 or 5% DMSO and 5% Cremphor EL. Drugs were delivered in a constant volume of 2 mL/kg (rat) and containing 3, 10 or 20 mg/kg of Nelivaptan. Rats were evaluated for stress response in a Punished Drinking Test, in an elevated Plus-Maze and a forced swim test. Doses of 3 and 10 mg/kg significantly increased punished drinking. A dose of 10 and 30 mg/kg increased the boldness of rats in the elevated maze test. In the forced swim test, nelivaptan had a significant effect on the immobility time at doses of 10 mg/kg and up.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11861823
CHO-dhFr- cells were transfected with an expression vector derived from plasmid 7055 containing the cDNA encoding the human V1b receptor. Stabley transfected cells were grown in 10 mM HEPES, pH 7.4, minimal essential medium supplemented with 5% fetal calf serum and 8 g/L sodium bicarbonate and 300 micro-G.mL geneticin at 37 deg-C and under a 5% CO2 atmosphere. Binding assays on membranes of CHO cells transfected with the human or rat V1b receptor were performed in an incubation medium containing 50 mM Tris-HCl, pH 7.4; 3 mM MgSO4; 0.1% BSA; 0.1% bacitracin; [3H]AVP; and increasing amounts of Nelivaptan (0.9, 1.8, 3.7, 7.5, and 15 nM). Nonspecific binding was determined in the presence of 1 μM unlabeled AVP. Nelivaptan dose-dependently antagonized [3H]AVP binding to various membrane preparations from CHO cell lines transfected with the rat and human V1b receptors. Nelivaptan had an affinity for human V1b receptors close to that of the natural hormone, AVP (Ki values of 1.54 ± 0.82 and 0.80 ± 0.25 nM, respectively)
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:26:20 GMT 2023
by
admin
on
Fri Dec 15 16:26:20 GMT 2023
|
Record UNII |
3TY57MQ4OA
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C2180
Created by
admin on Fri Dec 15 16:26:20 GMT 2023 , Edited by admin on Fri Dec 15 16:26:20 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C132046
Created by
admin on Fri Dec 15 16:26:20 GMT 2023 , Edited by admin on Fri Dec 15 16:26:20 GMT 2023
|
PRIMARY | |||
|
8903
Created by
admin on Fri Dec 15 16:26:20 GMT 2023 , Edited by admin on Fri Dec 15 16:26:20 GMT 2023
|
PRIMARY | |||
|
NELIVAPTAN
Created by
admin on Fri Dec 15 16:26:20 GMT 2023 , Edited by admin on Fri Dec 15 16:26:20 GMT 2023
|
PRIMARY | |||
|
439687-69-1
Created by
admin on Fri Dec 15 16:26:20 GMT 2023 , Edited by admin on Fri Dec 15 16:26:20 GMT 2023
|
PRIMARY | |||
|
DTXSID7047358
Created by
admin on Fri Dec 15 16:26:20 GMT 2023 , Edited by admin on Fri Dec 15 16:26:20 GMT 2023
|
PRIMARY | |||
|
9895468
Created by
admin on Fri Dec 15 16:26:20 GMT 2023 , Edited by admin on Fri Dec 15 16:26:20 GMT 2023
|
PRIMARY | |||
|
DB12643
Created by
admin on Fri Dec 15 16:26:20 GMT 2023 , Edited by admin on Fri Dec 15 16:26:20 GMT 2023
|
PRIMARY | |||
|
3TY57MQ4OA
Created by
admin on Fri Dec 15 16:26:20 GMT 2023 , Edited by admin on Fri Dec 15 16:26:20 GMT 2023
|
PRIMARY | |||
|
CHEMBL582857
Created by
admin on Fri Dec 15 16:26:20 GMT 2023 , Edited by admin on Fri Dec 15 16:26:20 GMT 2023
|
PRIMARY | |||
|
300000034349
Created by
admin on Fri Dec 15 16:26:20 GMT 2023 , Edited by admin on Fri Dec 15 16:26:20 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|